News ID: 274215
Published: 1030 GMT September 15, 2020

China coronavirus vaccine may be ready for public in November: Official

China coronavirus vaccine may be ready for public in November: Official
AFP

Coronavirus vaccines being developed in China may be ready for use by the general public as early as November, an official with the Chinese Center for Disease Control and Prevention (CDC) said.

China has four COVID-19 vaccines in the final stage of clinical trials. At least three of those have already been offered to essential workers under an emergency use program launched in July, Reuters reported.

Phase 3 clinical trials were proceeding smoothly and the vaccines could be ready for the general public in November or December, CDC chief biosafety expert Guizhen Wu said in an interview with state TV late on Monday.

Wu, who said she has experienced no abnormal symptoms in recent months after taking an experimental vaccine herself in April, did not specify which vaccines she was referring to.

A unit of state pharmaceutical giant China National Pharmaceutical Group (Sinopharm) and US-listed Sinovac Biotech are developing the three vaccines under the state’s emergency use program. A fourth COVID-19 vaccine being developed by CanSino Biologics was approved for use by the Chinese military in June.

Sinopharm said in July that its vaccine could be ready for public use by the end of this year after the conclusion of Phase 3 trials.

Global vaccine makers are racing to develop an effective vaccine against the virus which has killed more than 925,000 people. Leading Western vaccine makers pledged earlier this month to uphold scientific study standards and reject any political pressure to rush the process.

Pharma giant AstraZeneca and Oxford University said they had resumed a COVID-19 vaccine trial after getting the all-clear from British regulators, following a pause caused by a UK volunteer falling ill.

"Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so," the company said in a statement.

Last Wednesday, AstraZeneca announced it had "voluntarily paused" its trial of the vaccine developed alongside Oxford University after the volunteer developed an unexplained illness.

 

   
KeyWords
 
Comments
Comment
Name:
Email:
Comment:
Security Key:
Captcha refresh
Page Generated in 0/2175 sec